Core Viewpoint - Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) dropped approximately 40% intraday following the FDA's identification of deficiencies in its New Drug Application (NDA) for Anaphylm, an experimental treatment for severe allergic reactions, including anaphylaxis [1] Group 1 - The FDA's findings prevent discussions regarding labeling and post-marketing requirements, raising concerns about the approvability of the application ahead of the January 31, 2026, PDUFA action date [1]

Core Viewpoint - Aquestive Therapeutics, Inc. has faced a significant decline in its stock price due to the FDA identifying deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company's stock is traded on NASDAQ under the ticker symbol AQST [4]. Group 2: Recent Developments - Shares of Aquestive Therapeutics plunged approximately 40% intraday following the FDA's notification regarding deficiencies in its New Drug Application for Anaphylm [5]. - The FDA's findings currently prevent discussions on labeling and post-marketing requirements, which raises concerns about the application's likelihood of approval [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [4][5]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ja ...

… Last Friday, Aquestive got slapped down by the FDA, and the stock plunged 37% in a single session before losing another 15% this week… Despite the ambiguous slap down from the FDA, Aquestive maintains that all of its engagement with the FDA has been ‘highly collaborative.’ And the management said that since they received the letter, the FDA has repeatedly said the review of Anaphylm remains ongoing. These guys still sound really confident about their drug and their ability to get it approved both here and ...

Core Insights - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% intraday following the disclosure of deficiencies identified by the U.S. Food and Drug Administration (FDA) in its New Drug Application (NDA) for Anaphylm, an experimental treatment for severe allergic reactions [5] Group 1 - The FDA's identification of deficiencies prevents discussions regarding labeling and post-marketing requirements, raising concerns about the approvability of the NDA ahead of the January 31, 2026, PDUFA action date [5] - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses [2][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Aquestive Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices following a significant stock price drop due to FDA notification of deficiencies in a New Drug Application [1][2]. Investigation Details - On January 9, 2026, Aquestive disclosed that the FDA identified deficiencies in its New Drug Application for Anaphylm™ (epinephrine) Sublingual Film, which is intended for treating severe allergic reactions, including anaphylaxis. This notification has precluded discussions regarding labeling and post-marketing commitments for the product [2]. Next Steps - Investors who purchased or acquired Aquestive shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. The firm offers consultations without any cost or obligation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and consumer protection cases. The firm operates nationwide and handles cases in both federal and state courts [4].

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, impacting its market commitments and labeling discussions [1]. Company Summary - On January 9, 2026, Aquestive announced it received a letter from the FDA regarding deficiencies in its NDA application for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1]. - Following this announcement, Aquestive's stock price dropped by $2.18, representing a 35.1% decline, opening at $4.03 [2]. Legal Context - Levi & Korsinsky LLP has initiated an investigation into Aquestive Therapeutics, focusing on potential recovery options for investors who may have suffered losses due to the recent developments [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [3].

Core Viewpoint - The stock price of Aquestive Therapeutics (AQST) has recently experienced a significant decline of 45.2% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with selling pressure likely subsiding, which could lead to a bullish trend [2][5]. - A hammer pattern is characterized by a small candle body with a long lower wick, indicating that despite a downtrend, buying interest has emerged to push the stock price up towards the opening price [4][5]. - The effectiveness of the hammer pattern as a bullish indicator is enhanced when used alongside other bullish indicators [6]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for AQST, which is a bullish sign indicating potential price appreciation in the near term [7]. - The consensus EPS estimate for AQST has increased by 1.3% over the last 30 days, reflecting analysts' agreement on the company's improved earnings potential [8]. - AQST holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically indicates strong market performance [9][10].

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious medical conditions, including anaphylaxis [1]. - The company’s stock price fell by $2.18 (35.1%) to open at $4.03 in response to the FDA's findings [2]. Group 2: Regulatory Impact - The FDA's letter indicates that the deficiencies in the NDA application preclude any discussions regarding labeling and post-market commitments for Anaphylm [1]. - This regulatory setback could have significant implications for the company's market position and future revenue potential [1]. Group 3: Legal Implications - Levi & Korsinsky has initiated an investigation into the company, indicating potential legal ramifications for shareholders who may have suffered losses [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [3].